Second Sight Medical Products, Inc. Stock

$1.27

0.79% yesterday

Nasdaq, Aug 12, 10:08 pm CET

ISIN

US81362J1007

Symbol

VANI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Second Sight Medical Products, Inc. Stock price

$1.27

-1.35 51.56% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

+0.01 0.79%

ISIN

US81362J1007

Symbol

VANI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$74.7m

Enterprise Value

$61.6m

Net debt

positive

Cash

$13.0m

Shares outstanding

59.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

6.4

Financial Health

Equity Ratio

42.4%

Return on Equity

-130.6%

ROCE

-85.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-24.6m | -

EBIT

$-25.0m | $-27.6m

Net Income

$-23.8m | $-23.9m

Free Cash Flow

$-21.8m

EPS

$-0.4

FCF per Share

$-0.4

Short interest

0.9%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Second Sight Medical Products, Inc. Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Second Sight Medical Products, Inc. forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Second Sight Medical Products, Inc. forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Second Sight Medical Products, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	8.77 8.77	11% 11% -
- Research and Development Expense	16 16	3% 3% -
EBITDA	-25 -25	6% 6% -
- Depreciation and Amortization	0.40 0.40	14% 14% -
EBIT (Operating Income) EBIT	-25 -25	6% 6% -
Net Profit	-24 -24	6% 6% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Second Sight Medical Products, Inc. Stock News

Positive

Seeking Alpha

●

3 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.

Neutral

GlobeNewsWire

●

3 months ago

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025

Neutral

GlobeNewsWire

●

3 months ago

Vivani Medical to Present at the American Association of Pharmaceutical Scientists' “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists' (AAPS) “Beyond GLP1s: Wher...

More Second Sight Medical Products, Inc. News

Company Profile

Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.

Head office	United States
CEO	Adam Mendelsohn
Employees	37
Founded	2003
Website	vivani.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now